Recombinant CD38 (Daratumumab Biosimilar) anticorps

N° du produit ABIN7795093

Cet anticorps anti-CD38 (Daratumumab Biosimilar) Monoclonal Souris (ABIN7795093) détecte spécifiquement CD38 (Daratumumab Biosimilar) dans FACS et in vivo. L’anticorps est réactif avec des échantillons de Humain.

Aperçu rapide pour Recombinant CD38 (Daratumumab Biosimilar) anticorps (ABIN7795093)

Antigène: CD38 (Daratumumab Biosimilar)

Type d'anticorp: Recombinant Antibody

Reactivité: Humain

Hôte: Souris

Clonalité: Monoclonal

Conjugué: Cet anticorp CD38 (Daratumumab Biosimilar) est non-conjugé

Application: Flow Cytometry (FACS), In vivo Studies (in vivo)

Classe de qualité: Research Grade

Détail du produit anti-CD38 (Daratumumab Biosimilar) anticorps

Expression System: Mammalian cells

Fonction: Daratumumab Biosimilar, CD38 Monoclonal Antibody

Attributs du produit: Daratumumab Biosimilar uses the same protein sequences as the therapeutic antibody daratumumab. Daratumumab (Anti-Human CD38) is the first-in-class human-specific anti-CD38 monoclonal antibody. Daratumumab has anti-multiple myeloma (MM) effect. Daratumumab impairs MM cell adhesion, which results in an increased sensitivity of MM to proteasome inhibition.

Purification: Protein A or G affinity column

Pureté: >95 % by reducing SDS-PAGE

niveau d'endotoxine: < 1 EU per 1 mg of the protein by the LAL method

Immunogène: Human CD38

Information d'application

Indications d'application: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Stockage

Format: Liquid

Concentration: > 3 mg/mL

Stock: 4 °C,-20 °C

Stockage commentaire: Short time 2 to 8°C as supplied. Long time -20°C to -70°C as supplied.

Détails sur CD38 (Daratumumab Biosimilar)

Antigène: CD38 (Daratumumab Biosimilar)

Autre désignation: Daratumumab Biosimilar

Classe de substances: Biosimilar